Overview
SYRE market data
Price History
SYRE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.42 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.94 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.51 – $105.09 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $8.5K · P/B 3.55 · P/S 6,909.88.
Company News
Wolfe Research Downgrades Spyre Therapeutics to Peer PerformBenzinga · Jul 28, 2026, 4:17 PM
Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 14, 2026, 4:38 PM
Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120Benzinga · Jul 13, 2026, 10:50 AM
Rivian, Micron And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Jul 7, 2026, 12:05 PM
Spyre Therapeutics Files Prospectus For Offering Mixed Shelf; Terms UndisclosedBenzinga · Jun 26, 2026, 8:15 PM
What's Going On With Spyre Therapeutics Stock On Wednesday?Benzinga · Jun 24, 2026, 4:01 PM
FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga · Jun 24, 2026, 12:05 PM
Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $135Benzinga · Jun 23, 2026, 1:45 PM
Spyre Therapeutics Announces 12-Week Induction Data From Part A Of Phase 2 SKYLINE Study Of SPY002 To Treat Active Ulcerative Colitis Meets Primary Endpoint; SPY002 Well Tolerated With Consistent Safety ProfileBenzinga · Jun 15, 2026, 12:15 PM
8-K filing — Spyre Therapeutics, Inc. (SYRE)SEC EDGAR · Jun 15, 2026, 12:01 PM